S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
3 lithium stocks to ride a multi-year cycle
Is Gold Really Boring? (Ad)
Goldman upgraded Nvidia stock, one metric says it could go higher
Autozone stock price is still in the rally zone
Is Gold Really Boring? (Ad)
Closing prices for crude oil, gold and other commodities
New highs are coming for Lowe’s stock despite mixed results
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Consumer confidence slips in February as anxiety over potential recession surprisingly reappears
Beyond Meat's shares soar on better-than-expected Q4 revenue despite weak US sales
S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
3 lithium stocks to ride a multi-year cycle
Is Gold Really Boring? (Ad)
Goldman upgraded Nvidia stock, one metric says it could go higher
Autozone stock price is still in the rally zone
Is Gold Really Boring? (Ad)
Closing prices for crude oil, gold and other commodities
New highs are coming for Lowe’s stock despite mixed results
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Consumer confidence slips in February as anxiety over potential recession surprisingly reappears
Beyond Meat's shares soar on better-than-expected Q4 revenue despite weak US sales
S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
3 lithium stocks to ride a multi-year cycle
Is Gold Really Boring? (Ad)
Goldman upgraded Nvidia stock, one metric says it could go higher
Autozone stock price is still in the rally zone
Is Gold Really Boring? (Ad)
Closing prices for crude oil, gold and other commodities
New highs are coming for Lowe’s stock despite mixed results
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Consumer confidence slips in February as anxiety over potential recession surprisingly reappears
Beyond Meat's shares soar on better-than-expected Q4 revenue despite weak US sales
S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
3 lithium stocks to ride a multi-year cycle
Is Gold Really Boring? (Ad)
Goldman upgraded Nvidia stock, one metric says it could go higher
Autozone stock price is still in the rally zone
Is Gold Really Boring? (Ad)
Closing prices for crude oil, gold and other commodities
New highs are coming for Lowe’s stock despite mixed results
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Consumer confidence slips in February as anxiety over potential recession surprisingly reappears
Beyond Meat's shares soar on better-than-expected Q4 revenue despite weak US sales
NYSEARCA:XPH

SPDR S&P Pharmaceuticals ETF (XPH) Price, Holdings, & News

$45.55
+0.31 (+0.69%)
(As of 02/27/2024 ET)
Today's Range
$45.18
$45.62
50-Day Range
$39.76
$45.55
52-Week Range
$34.67
$45.62
Volume
21,886 shs
Average Volume
49,347 shs
Market Capitalization
$239.14 million
Assets Under Management
$228.40 million
Dividend Yield
1.47%
Net Expense Ratio
0.35%

About SPDR S&P Pharmaceuticals ETF

SPDR S&P Pharmaceuticals ETF (the Fund) seeks to replicate as closely as possible the total return performance of the S&P Pharmaceuticals Select Industry Index. The S&P Pharmaceuticals Select Industry Index represents the pharmaceuticals sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Fund invests substantially all, but at least 80%, of its total assets in the securities comprising the Index. In addition, the Fund may invest in equity securities that are not included in the Index, cash and cash equivalents or money market instruments, such as repurchase agreements and money market funds. The Pharmaceuticals Index is a modified equal weight index. SSgA Funds Management, Inc. is the Fund's investment advisor.

XPH Stock Price History

XPH ETF News Headlines

Pharmaceutical Stocks - Best Pharmaceutical Stocks to Buy (XPH)
Along with biotechnology and biotech companies, the pharma industry is a major part of the overall healthcare market. Pharmaceutical companies include some of the biggest stock gainers and some of the best growth stocks on the market. The pharmaceutical market has many amazing stocks to watch. The pharma industry may also be a good investment for those looking for dividend stocks since so many of the largest pharmaceutical companies pay a dividend to its shareholders. Though the industry has plenty of potential for growth, investors should also be aware that pharma stocks—especially smaller startups—can be risky. Investors buying pharma stocks should make sure to do their research and only invest in pharma stocks as part of a diversified portfolio.
SPDR S&P Pharmaceuticals ETF
Hunting for Domestic Vanadium - The U.S. Govt. Did WHAT?
A little-known metal called vanadium is vital to American national security and energy independence. But right now, China and Russia dominate our supply. The U.S. Govt. is so serious about vanadium, it funded and recently completed an "Earth MRI" survey to seek out new sources of this energy metal - in Wyoming.
XPH ETF Stock Price History
Hunting for Domestic Vanadium - The U.S. Govt. Did WHAT?
A little-known metal called vanadium is vital to American national security and energy independence. But right now, China and Russia dominate our supply. The U.S. Govt. is so serious about vanadium, it funded and recently completed an "Earth MRI" survey to seek out new sources of this energy metal - in Wyoming.
ETF Watch: Fortitude, Not Fashion Wins Out
See More Headlines
Receive XPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for SPDR S&P Pharmaceuticals ETF and its competitors with MarketBeat's FREE daily newsletter.

Fund Details

Issuer
SSgA
Fund Name
SPDR S&P Pharmaceuticals ETF
Tax Classification
Regulated Investment Company
Current Symbol
NYSEARCA:XPH
Inception Date
6/19/2006
Fund Manager
Michael Feehily, Karl Schneider, Keith Richardson

Fund Focus

Asset Class
Equity
Benchmark
S&P Pharmaceuticals Index
Category
Sector
Focus
Health Care
Development Level
Developed Markets
Region
North America
Number of Holdings
36

Fund Statistics

Assets Under Management
$228.40 million
Average Daily Volume
$63,207.40
Discount/Premium
0.01%

Administrator, Advisor and Custodian

Administrator
SSgA Funds Management, Inc.
Advisor
SSgA Funds Management, Inc.
Custodian
State Street Bank and Trust Company
Distributor
State Street Global Advisors Funds Distributors, LLC
Transfer Agent
State Street Bank and Trust Company
Trustee
N/A
Lead Market Maker
Citadel

Options

Optionable
Optionable
Options Volume
1
Put Options
217
Call Options
1
Short Interest
295,800 shs

Miscellaneous

Beta
0.84
Creation Unit
50,000
Creation Fee
$250.00
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

SPDR S&P Pharmaceuticals ETF Expenses

TypeXPHHealth Care ETFsEquity ETFsNYSEARCA ETFsAll ETFs
Management Fee0.35%0.57%0.54%0.50%0.51%
Other Expenses0.00%0.40%0.55%0.64%0.58%
Total Expense0.35%0.72%0.70%0.74%0.70%
Fee Waiver0.00%-0.53%-0.55%-0.69%-0.57%
Net Expense0.35%0.61%0.60%0.57%0.58%

SPDR S&P Pharmaceuticals ETF (XPH) Holdings & Exposure

Key Executives

  • James E. Ross (Age 52)
    President, Trustee
  • Peter A. Ambrosini (Age 69)
    Chief Compliance Officer
  • Michael P. Riley (Age 44)
    Vice President
  • Gary L. French (Age 64)
    Treasurer
  • John W. Clark (Age 46)
    Assistant Treasurer
  • Matthew W. Flaherty (Age 42)
    Assistant Treasurer
  • Chad C. Hallett (Age 47)
    Assistant Treasurer of Street tracks series trust
  • Mary Moran Zeven (Age 52)
    Secretary
  • Scott M. Zoltowski (Age 44)
    Assistant Secretary
  • Dave Kelly
    Independent Trustee














XPH ETF - Frequently Asked Questions

How have XPH shares performed in 2024?

SPDR S&P Pharmaceuticals ETF's stock was trading at $41.62 on January 1st, 2024. Since then, XPH shares have increased by 9.4% and is now trading at $45.55.
View the best growth stocks for 2024 here
.

What does XPH invest in?

SPDR S&P Pharmaceuticals ETF is a equity fund issued by SSgA. XPH focuses on health care investments and follows the S&P Pharmaceuticals Index. The fund's investments total to approximately $228.40 million assets under management.

What stocks does SPDR S&P Pharmaceuticals ETF hold?
What is the management fee for SPDR S&P Pharmaceuticals ETF?

SPDR S&P Pharmaceuticals ETF's management fee is 0.35% and has no other recorded expenses or fee waivers. The net expense ratio for XPH is 0.35%.

What other stocks do shareholders of SPDR S&P Pharmaceuticals ETF own?

Based on aggregate information from My MarketBeat watchlists, some companies that other SPDR S&P Pharmaceuticals ETF investors own include Pfizer (PFE), Bank of America (BAC), Micron Technology (MU), Broadcom (AVGO), Chevron (CVX), DocuSign (DOCU), SPDR Gold Shares (GLD), International Business Machines (IBM), JPMorgan Chase & Co. (JPM) and AT&T (T).

Who are SPDR S&P Pharmaceuticals ETF's major shareholders?

SPDR S&P Pharmaceuticals ETF's stock is owned by a variety of institutional and retail investors. Top institutional investors include Wells Fargo & Company MN (3.08%), Goldman Sachs Group Inc. (1.90%), BNP Paribas Financial Markets (1.08%), First Citizens Bank & Trust Co. (0.99%), Envestnet Portfolio Solutions Inc. (0.89%) and Wharton Business Group LLC (0.84%).

How do I buy shares of SPDR S&P Pharmaceuticals ETF?

Shares of XPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSEARCA:XPH) was last updated on 2/28/2024 by MarketBeat.com Staff

From Our Partners